Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
02/24/2023* -- Results Q4 2022 -- 3.11 --
11/08/2022 16:30 EST Earnings Call Q3 2022 -- -- --
11/08/2022 -- Results Q3 2022 -- -0.97 --
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/04/2022 -- Results Q2 2022 -0.97 -0.94 -2.75%
05/04/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/04/2022 -- Results Q1 2022 -1.19 -0.76 -57.41%
*Estimated Date/Time

Earnings

Next Report Date 02/24/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/08/2022
Beat/Miss Upgrade
Return Since 25.56%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
URL https://www.zymeworks.com
Investor Relations URL https://ir.zymeworks.com/
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
--
--
93.33%
209.7%
3.96%
-65.32%
-52.04%
21.88%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
6.11%
-22.43%
23.50%
-7.94%
20.43%
10.56%
-22.81%
25.05%
-2.35%
-14.98%
115.7%
50.55%
197.1%
-31.74%
65.37%
-81.11%
116.9%
-68.72%
-60.09%
-83.95%
-24.91%
3.66%
32.47%
-61.63%
-31.48%
-4.23%
-63.31%
123.4%
107.8%
17.32%
103.1%
26.22%
-4.51%
As of January 27, 2023.

Profile

Edit
Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
URL https://www.zymeworks.com
Investor Relations URL https://ir.zymeworks.com/
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ETCHX 33.09M USD 2.23%
NGM272 800548.0 USD 1.23%
BBC 181857.0 USD 1.10%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ZYME Tweets